Moderna Stock Jumps as Biotech Gets $590M From US To …
5 days ago · Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech firm's mRNA-1018 …
Moderna Secures $590M Funding From U.S. Government for Bird …
Jan 20, 2025 · This is the second time under a year that Moderna has secured funding from the U.S. government for its bird flu vaccine. Last July, the company was awarded $176 million by …
Moderna Announces Updates on Pandemic Influenza Program
CAMBRIDGE, MA / January 17, 2025 / Moderna, Inc. (NASDAQ: MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate …
Moderna, Inc. (MRNA) Latest Stock News & Headlines - Yahoo …
Get the latest Moderna, Inc. (MRNA) stock news and headlines to help you in your trading and investing decisions.
Moderna R&D day: $1 billion in cost cuts, 10 product launches
Sep 12, 2024 · Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline …
News Details - Moderna
Mar 27, 2024 · Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpoints. Expects two more Phase 3 readouts in …
News Details - Moderna
Jun 10, 2024 · CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1083, an investigational …
News Details - Moderna
Jan 8, 2024 · CAMBRIDGE, MA / ACCESSWIRE / January 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced business updates and progress on the Company's …
Moderna Awarded Tender for the Supply of Its mRNA ... - Markets …
2 days ago · This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: …
Moderna jumps as vaccine shows benefit in head and neck cancer …
Apr 9, 2024 · Moderna shares rose 8% to a three-month high on Tuesday after the company's individualized cancer vaccine developed with Merck showed positive response in an early …